Lymphadenopathy Associated Virus Infection of a Blood Donor—Recipient Pair with Acquired Immunodeficiency Syndrome

Feorino, Paul M.; Kalyanaraman, V. S.; Haverkos, Harry W.; Cabradilla, Cirilo D.; Warfield, Donna T.; Jaffe, Harold W.; Harrison, Alyne K.; Gottlieb, Michael; Goldfinger, Dennis; Chermann, J.-C.; Barré‐Sinoussi, Françoise; Spira, T. T.; McDougal, J. Steven; Curran, James W.; Montagnier, Luc; Murphy, Frederick A.; Francis, Donald P.

doi:10.1126/science.6328663

Cited by 174 publications

(41 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All of these data indicate HTLV-III to be the etiological agent for AIDS. A virus with similar properties, but described variously as lymphadenopathy-associated virus (9,10), immune deficiency-associated virus I, and immune deficiency-associated virus II (11), has been isolated from patients with lymphadenopathy and AIDS. In the present communication we describe the antigenic characteristics of the major core protein of HTLV-III.…”

mentioning

confidence: 99%

Immunological properties of the Gag protein p24 of the acquired immunodeficiency syndrome retrovirus (human T-cell leukemia virus type III).

Sarngadharan¹,

Bruch²,

Popovič³

et al. 1985

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

Antigenic cross-reactivity of human T-cell leukemia virus type III (HTLV-III) with HTLV-I and HTLV-II and other retroviruses was measured by using a stringent homologous competition radioimmunoassay for the Gag protein p24 and a less stringent electrophoretic transfer blot assay. In the competition radioimmunoassay only minimal crossreactivities were detected between HTLV-III p24 and both HTLV-I and HTLV-II. No cross-reactivity was detected with any other retrovirus. In the electrophoretic transfer blot system using rabbit antibody to HTLV-I, HTLV-II, and HTLV-III, low-level cross-reaction was detected between HTLV-I and HTLV-IH and between HTLV-II and HTLV-IIl. Unlike the cross-reactivity between HTLV-I p24 and HTLV-III p24, which was bidirectional, the one between HTLV-II and HTLV-III was only a one-way reactivity. Antiserum to HTLV-II recognized HTLV-III p24, but the antiserum to HTLV-III did not recognize HTLV-II p24. The results indicate that HTLV-III is a unique retrovirus with a limited homology with HTLV-I and HTLV-II but unrelated to most other retroviruses.The human retrovirus human T-cell leukemia virus type III (HTLV-III) was isolated from cultured T cells of several patients with acquired immunodeficiency syndrome (AIDS), or generalized lymphadenopathy, and from asymptomatic carriers of the virus (1-3). Like HTLV-I and HTLV-II, this new isolate has a preferential tropism for OKT4+ lymphocytes and contains a Mg2+-dependent reverse transcriptase (1, 2) and a major core protein of about 24,000 daltons (4). Unlike the first two subgroups, however, HTLV-Il does not transform T cells in vitro and the in vitro transmission of the virus to fresh human T-cells only results in a transient virus production (1, 2, 5, 6). The virus could be conveniently propagated in an immortalized human neoplastic cell line (HT) and several clones of this cell line (1). Seroepidemiological assays using this virus showed a nearly complete correlation between AIDS and antibodies to HTLV-III antigens (3, 4, 7). In addition, nearly 90% of patients with lymphadenopathy syndrome and a significant but lower proportion ("40%) of asymptomatic homosexual men at risk of AIDS also carry circulating antibodies to HTLV-Ill. All of a group of patients with no risk factors for AIDS who developed AIDS after receiving blood transfusions from blood donors who were themselves seropositive showed HTLV-III antibodies (unpublished results). All of these data indicate HTLV-III to be the etiological agent for AIDS. A virus with similar properties, but described variously as lymphadenopathy-associated virus (9, 10), immune deficiency-associated virus I, and immune deficiency-associated virus II (11), has been isolated from patients with lymphadenopathy and AIDS. In the present communication we describe the antigenic characteristics of the major core protein of HTLV-III. We show that HTLV-III is a unique retrovirus with some, albeit limited, cross-reactivities with HTLV-I and HTLV-II, but not detectably related to other viruses. In addition, ...

show abstract

mentioning

confidence: 99%

Immunological properties of the Gag protein p24 of the acquired immunodeficiency syndrome retrovirus (human T-cell leukemia virus type III).

Sarngadharan¹,

Bruch²,

Popovič³

et al. 1985

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

show abstract

“…Human T-cell leukemia/lymphotropic virus type III (HTLV-III) (1)(2)(3)(4), also named lymphadenopathy-associated virus (LAV) (5,6), is thought to be the primary cause of a spectrum of immunological disorders, with acquired immunodeficiency syndrome (AIDS) as the most severe clinical manifestation. The implication of HTLV-IIl as the causative agent was based primarily on the high correlation between development of disease and prior exposure to virus, evidenced by the isolation of virus (1,2) and the detection of antibodies to viral proteins in patient sera (3,4,7).…”

mentioning

confidence: 99%

Isolation of infectious human T-cell leukemia/lymphotropic virus type III (HTLV-III) from patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related complex (ARC) and from healthy carriers: a study of risk groups and tissue sources.

Salahuddin¹,

Markham²,

Popovič³

et al. 1985

Proc. Natl. Acad. Sci. U.S.A.

131

View full text Add to dashboard Cite

Acquired immunodeficiency syndrome (AIDS) and AIDS-related complex (ARC) are thought to be caused by human T-cell leukemia/lymphotropic virus type III (HTLV-Ill). Since (helper/inducer) lymphocytes were preferentially infected and were subjected to a characteristic cytopathic effect. The availability of multiple isolates of virus from a number of different patients and donors will greatly facilitate the characterization of HTLV-III and the study of possible biological and/or biochemical variants of the virus responsible for the development of AIDS, ARC, and related diseases.

show abstract

“…The original isolates, HTLV-III and LAV, are likely the same virus 19 and have been cultured from blood, semen, and saliva from patients with AIDS or lymphadenopathy syndrome and from asymptomatic individuals from high-risk groups. 1,3,4,11,[20][21][22][23][24][25][26][27] Antibody to these viruses has been detected in the serum of both asymptomatic and ill individuals from these risk groups. 1,3,4,[12][13][14][15][16] Antibody to HTLV-III/LAV has been detected in 34% 11 to 94% 12 asymptomatic hemophilic patients, a group at high risk for AIDS.…”

Section: Discussionmentioning

confidence: 99%

HTLV-III serology in hemophilia: Relationship with immunologic abnormalities

Gill

Menitove

Anderson

et al. 1986

The Journal of Pediatrics

View full text Add to dashboard Cite

Lymphadenopathy Associated Virus Infection of a Blood Donor—Recipient Pair with Acquired Immunodeficiency Syndrome

Cited by 174 publications

References 10 publications

Immunological properties of the Gag protein p24 of the acquired immunodeficiency syndrome retrovirus (human T-cell leukemia virus type III).

Immunological properties of the Gag protein p24 of the acquired immunodeficiency syndrome retrovirus (human T-cell leukemia virus type III).

Isolation of infectious human T-cell leukemia/lymphotropic virus type III (HTLV-III) from patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related complex (ARC) and from healthy carriers: a study of risk groups and tissue sources.

HTLV-III serology in hemophilia: Relationship with immunologic abnormalities

Contact Info

Product

Resources

About